HARMONY BIOSCIENCES HOLDINGS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.27 USD | -2.07% |
|
+3.56% | -6.28% |
| 30/04 | Harmony Biosciences Acquires Epygenix Therapeutics; Shares Rise | MT |
| 30/04 | Transcript : Harmony Biosciences Holdings, Inc., Q1 2024 Earnings Call, Apr 30, 2024 |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,057 | 2,493 | 3,268 | 1,892 | 1,719 | - | - |
| Enterprise Value (EV) 1 | 2,022 | 2,449 | 3,214 | 1,759 | 1,427 | 1,195 | 913 |
| P/E ratio | -14.6 x | 73.5 x | 18.6 x | 15.2 x | 12.4 x | 7.66 x | 5.95 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 12.9 x | 8.16 x | 7.46 x | 3.25 x | 2.41 x | 2.04 x | 1.74 x |
| EV / Revenue | 12.7 x | 8.02 x | 7.34 x | 3.02 x | 2 x | 1.42 x | 0.92 x |
| EV / EBITDA | 74.2 x | 23 x | 22.4 x | 8.13 x | 6.89 x | 3.44 x | 2.28 x |
| EV / FCF | -677 x | 24.9 x | 22.3 x | 8.03 x | 6.21 x | 4.16 x | 2.67 x |
| FCF Yield | -0.15% | 4.01% | 4.49% | 12.5% | 16.1% | 24% | 37.5% |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 56,889 | 58,472 | 59,318 | 58,572 | 56,792 | - | - |
| Reference price 2 | 36.15 | 42.64 | 55.10 | 32.30 | 30.27 | 30.27 | 30.27 |
| Announcement Date | 25/03/21 | 28/02/22 | 21/02/23 | 22/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 159.7 | 305.4 | 437.9 | 582 | 712 | 843.1 | 990.6 |
| EBITDA 1 | 27.26 | 106.4 | 143.6 | 216.4 | 207 | 347.4 | 400.6 |
| EBIT 1 | 16.99 | 87.53 | 120.2 | 192 | 200.3 | 312.8 | 395.3 |
| Operating Margin | 10.63% | 28.66% | 27.45% | 32.99% | 28.13% | 37.1% | 39.91% |
| Earnings before Tax (EBT) 1 | -36.94 | 37.43 | 104.7 | 173.4 | 184 | 308 | 395 |
| Net income 1 | -63.85 | 34.6 | 181.5 | 128.9 | 148 | 238.2 | 299.7 |
| Net margin | -39.97% | 11.33% | 41.44% | 22.14% | 20.78% | 28.25% | 30.26% |
| EPS 2 | -2.480 | 0.5800 | 2.970 | 2.130 | 2.441 | 3.951 | 5.090 |
| Free Cash Flow 1 | -2.987 | 98.26 | 144.3 | 219.1 | 229.7 | 287 | 342.2 |
| FCF margin | -1.87% | 32.17% | 32.95% | 37.64% | 32.26% | 34.04% | 34.55% |
| FCF Conversion (EBITDA) | - | 92.38% | 100.5% | 101.24% | 110.97% | 82.62% | 85.42% |
| FCF Conversion (Net income) | - | 284.01% | 79.51% | 170.02% | 155.23% | 120.48% | 114.18% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 25/03/21 | 28/02/22 | 21/02/23 | 22/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 91.21 | 85.31 | 107 | 117.2 | 128.3 | 119.1 | 134.2 | 160.3 | 168.4 | 154.6 | 173.7 | 187.4 | 197.3 | 181.7 | 205 |
| EBITDA | - | - | - | - | - | - | 52.97 | - | - | - | - | - | - | - | - |
| EBIT 1 | 28.63 | 27.56 | 33.12 | 11.9 | 47.61 | 40.42 | 46.9 | 64.51 | 40.2 | 52.03 | 21.03 | 57.92 | 58.52 | 62.18 | 70.57 |
| Operating Margin | 31.39% | 32.3% | 30.94% | 10.15% | 37.11% | 33.93% | 34.95% | 40.25% | 23.87% | 33.65% | 12.1% | 30.9% | 29.66% | 34.23% | 34.43% |
| Earnings before Tax (EBT) 1 | 24.48 | 23.38 | 29.23 | 7.967 | 44.1 | 37.78 | 44.1 | 51.83 | 39.69 | 51.78 | 22.65 | 54.22 | 53.68 | 60.03 | 68.47 |
| Net income 1 | 22.71 | 21.48 | 23.53 | 87.79 | 48.51 | 29.48 | 34.3 | 38.47 | 26.61 | 38.33 | 16.99 | 40.75 | 40.45 | 45.53 | 52.03 |
| Net margin | 24.9% | 25.18% | 21.99% | 74.91% | 37.81% | 24.75% | 25.56% | 24% | 15.8% | 24.79% | 9.78% | 21.74% | 20.5% | 25.06% | 25.38% |
| EPS 2 | 0.3800 | 0.3500 | 0.3900 | 1.440 | 0.7900 | 0.4800 | 0.5600 | 0.6300 | 0.4500 | 0.6700 | 0.2443 | 0.7300 | 0.7414 | 0.7533 | 0.8467 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 28/02/22 | 03/05/22 | 02/08/22 | 01/11/22 | 21/02/23 | 02/05/23 | 01/08/23 | 31/10/23 | 22/02/24 | 30/04/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | 34.4 | 44.3 | 54.1 | 133 | 292 | 524 | 806 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -2.99 | 98.3 | 144 | 219 | 230 | 287 | 342 |
| ROE (net income / shareholders' equity) | - | - | - | 29.6% | 37.7% | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share 2 | - | - | - | 3.630 | 3.720 | 4.650 | - |
| Capex 1 | 0 | 0.3 | 0.17 | 0.31 | 0.37 | 0.85 | 1.36 |
| Capex / Sales | 0% | 0.1% | 0.04% | 0.05% | 0.05% | 0.1% | 0.14% |
| Announcement Date | 25/03/21 | 28/02/22 | 21/02/23 | 22/02/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
30.27
USD
Average target price
42.25
USD
Spread / Average Target
+39.58%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.28% | 1.76B | |
| +33.25% | 704B | |
| +28.59% | 577B | |
| -3.55% | 348B | |
| +18.16% | 327B | |
| +4.36% | 288B | |
| +14.81% | 234B | |
| +4.93% | 198B | |
| -9.78% | 194B | |
| -3.69% | 147B |
- Stock Market
- Equities
- HRMY Stock
- Financials Harmony Biosciences Holdings, Inc.
